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Background: Excessive bone resorption by osteoclasts causes pathological bone destruction, seen in various bone
diseases. There is accumulating evidence that certain herbal extracts have beneficial effects on bone metabolism.
The fruits of Alpinia oxyphylla has been traditionally used for the treatment of diarrhea and enuresis. In this study,
we investigated the effects of water extract of the fruits of Alpinia oxyphylla (WEAO) on osteoclast differentiation
and osteoclast-mediated bone destruction.
Methods: For osteoclast differentiation assay, mouse bone marrow-derived macrophages (BMMs) were cultured in the
presence of RANKL and M-CSF. RANKL signaling pathways and gene expression of transcription factors regulating
osteoclast differentiation were investigated by real-time PCR and Western blotting. A constitutively active form of
NFATc1 was retrovirally transduced into BMMs. Bone resorbing activity of mature osteoclast was examined on a
plate coated with an inorganic crystalline calcium phosphate. The in vivo effect against bone destruction was
assessed in a murine model of RANKL-induced osteoporosis by micro-computed tomography and bone
metabolism marker analyses.
Results: WEAO dose-dependently inhibited RANKL-induced osteoclast differentiation from BMMs by targeting
the early stages of osteoclast differentiation. WEAO inhibited RANKL-induced expression of NFATc1, the master
regulator of osteoclast differentiation. Overexpression of a constitutively active form of NFATc1 blunted the
inhibitory effect of WEAO on osteoclast differentiation, suggesting that NFATc1 is a critical target of the
inhibitory action of WEAO. WEAO inhibited RANKL-induced expression of c-Fos, an upstream activator of NFATc1,
by suppressing the classical NF-κB signaling pathway. WEAO also inhibited RANKL-induced down-regulation of Id2 and
MafB, negative regulators of NFATc1. WEAO does not directly affect bone resorbing activity of mature osteoclasts. In
accordance with the in vitro results, WEAO attenuated RANKL-induced bone destruction in mice by inhibiting
osteoclast differentiation.
Conclusions: This study demonstrates that WEAO exhibits a protective effect against bone loss by inhibiting
RANKL-induced osteoclast differentiation. These findings suggest that WEAO might be useful for the prevention
and treatment of bone diseases associated with excessive bone resorption.
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Bone is a dynamic organ that undergoes continuous re-
modeling through osteoclast-mediated bone resorption
and osteoblast-mediated bone formation. The bone re-
modeling process is highly controlled by various factors
and is necessary to repair damaged bone and to main-
tain mineral homeostasis [1,2].* Correspondence: jyma@kiom.re.kr
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unless otherwise stated.Osteoclasts are unique, multinucleated giant cells that
form through fusion of monocyte/macrophage lineage
precursor cells. Macrophage colony-stimulating factor
(M-CSF) and receptor activator of NF-κB ligand (RANKL)
are critical cytokines required for osteoclast differentiation
[3-5]. M-CSF supports the survival and proliferation of
osteoclast precursors [6]. In addition, M-CSF stimulates
the expression of RANK, the receptor for RANKL, in
osteoclast precursors [5]. The binding of RANKL to
RANK receptor on osteoclast precursors activate downThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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activated protein kinases (MAPKs) and NF-κB by
recruiting adaptor molecules such as tumor necrosis
factor receptor-associated factor 6, which regulate tran-
scription factors involved in osteoclast differentiation
[7-10]. Accumulating evidence suggests that nuclear
factor of activated T cells cytoplasmic 1 (NFATc1) inte-
grates RANKL signaling for terminal differentiation of
osteoclasts [1]. Conditional deletion of NFATc1 in the
myeloid cell lineage results in osteoclast-poor osteope-
trosis, and NFATc1-deficient osteoclast precursors fails
to differentiate into osteoclasts in vitro [11]. In addition,
overexpression of NFATc1 can induce the differenti-
ation of osteoclast precursors into mature osteoclasts
even in the absence of RANKL [12]. Thus, NFATc1 is
considered the master regulator of osteoclast differenti-
ation. RANKL stimulates the expression and activation of
NFATc1 in osteoclast precursors by regulating other tran-
scription factors. It has been shown that RANKL-induced
NFATc1 expression depends on NF-κB and c-Fos, which
are activated by RANKL [9,12]. It was also reported that
RANKL suppresses the expression of transcriptional
repressors such as inhibitors of differentiation/DNA
binding (Ids), v-maf musculoaponeurotic fibrosarcoma
oncogene family protein B (MafB), and interferon regu-
latory factor 8 that inhibit NFATc1 expression and
osteoclast differentiation [13].
The RANKL/RANK pathway is not only crucial for
normal bone remodeling but also primarily responsible
for pathological bone destruction in various bone dis-
eases such as postmenopausal osteoporosis, Paget’s
disease, rheumatoid arthritis, and lytic bone metastasis.
Thus, the RANKL/RANK pathway is considered to be
an attractive therapeutic target for bone destructive dis-
eases [2]. There is a growing interest in herbal resources
including common vegetables and fruits as a promising
approach for the prevention and treatment of bone-
related disorders such as osteoporosis [14,15]. We evalu-
ated the inhibitory effects of various herbal extracts on
RANKL-induced osteoclast differentiation from its pre-
cursor cells as a screen for potential herbal candidates
with bone protective properties. Water extract of the
fruits of Alpinia oxyphylla (WEAO) was found to have
a relatively strong inhibitory activity against osteoclast
differentiation. The fruits of A. oxyphylla, called Yizhi,
Yakuchi, and Ikji in Chinese, Japanese, and Korean, re-
spectively, has been traditionally used for the treatment
of diarrhea and enuresis [16]. Pharmacological studies
have shown that the fruits of A. oxyphylla possess
a wide range of biological activities, including anti-
diarrheal [17], anti-tumor [18], anti-anaphylactic [19],
anti-ulcer [20], and neuroprotective [21,22] activities.
However, the effect of the fruits of A. oxyphylla on




Fetal bovine serum (FBS), α-modified minimal essential
medium (α-MEM), and penicillin/streptomycin were pur-
chased from Gibco BRL Life Technologies (Grand Island,
NY, USA). Recombinant M-CSF and RANKL were obtained
as described previously [23]. 1α,25-dihydroxyvitamin D3,
prostaglandin E2, and chrysin were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Tectochrysin and nootkatone
were obtained from ChemFaces (Wuhan, China). Anti-
bodies against phospho-JNK1/2 (Thr183/Tyr185), JNK,
phospho-p38 (Thr180/Tyr182), p38, phospho-IκBα (Ser32),
and IκBα were obtained from Cell singling Technology
(Danvers, MA, USA). Antibodies against NFATc1 and c-Fos
were purchased from Santa Cruz biotechnology (Santa
Cruz, CA, USA).
Preparation of WEAO
Air-dried fruits of A. oxyphylla were obtained from
Yeongcheon Oriental Herbal Market (Yeongcheon,
Korea) and authenticated by an expert botanist, emeritus
Prof. Ki-Hwan Bae (Collage of Pharmacy, Chungnam
National University). A voucher specimen was deposited
at the herbarium of the KM-Based Herbal Drug Devel-
opment Group, Korea Institute of Oriental Medicine.
The materials were extracted by boiling in distilled water
(1:10, w/v) for 3 h. The water extract was filtered with
standard sieves (106 μm; Restsch, Haan, Germany) and
then lyophilized. The lyophilized powder (yield: 5.52% of
dried fruits) was re-suspended in distilled water and cen-
trifuged at 10,000 g for 5 min to prepare WEAO. For
in vitro experiments, WEAO was filtered through a
0.2 μm filter.
High performance liquid chromatography (HPLC) analysis
HPLC analysis of WEAO was conducted using a Hitachi
LaChrom Elite HPLC system (Hitachi High Technologies
Corp., Tokyo, Japan). The chromatographic separation
was carried out using a Kinetex C8 column (4.6 mm×
100 mm, 2.6 μm, 40 °C). The mobile phase was 0.1% tri-
fluoroacetic acid in deionized water (A) and acetonitrile
(B) with a step gradient elution (0–3 min, 5%–5% B; 3–
63 min, 5%–70% B; 63–73 min, 70%–70% B). A mixture
of standard compounds (Chrysin, Tectochrysin, Nootka-
tone; each 200 μg/mL) and WEAO (100 mg/mL) were dis-
solved in methanol and filtered through a 0.2 μm syringe
filter prior to injection for HPLC analysis.
Osteoclast differentiation assay
Bone marrow cells were collected by flushing the femurs
and tibias from 6- to 7-week-old male ICR mice with α-
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pared from bone marrow cells with M-CSF (60 ng/mL)
in α-MEM complete medium containing 10% FBS and
1% penicillin/streptomycin as described previously [24].
For osteoclast differentiation, BMMs (1 × 104 cells/well
in a 96-well plate) were cultured in α-MEM complete
medium supplemented with M-CSF (60 ng/mL) and
RANKL (100 ng/mL) for 4 days. To investigate the effect
of WEAO on osteoclast differentiation, WEAO was
added to the cultures simultaneously with RANKL at
day 0 or after 1, 2, or 3 days. Cells were replenished with
fresh medium and treatments on the third day of cul-
ture. To assess osteoclast differentiation, cells were
stained for tartrate-resistant acid phosphatase (TRAP)
activity as described below. TRAP-positive multinucle-
ated cells containing more than three nuclei and larger
than 100 μm in diameter were counted as osteoclasts.
TRAP assay
TRAP staining was performed using TRAP buffer (50 mM
sodium tartrate and 0.12 M sodium acetate, pH 5.2)
with naphthol AS-MX phosphate and fast red violet LB
salt (Sigma-Aldrich) as described previously [23]. Serum
TRAP isoenzyme 5b (TRAP 5b) activity was determined
using the fluorogenic substrate, naphthol AS-BI phosphate
(Sigma-Aldrich). In brief, 20 μL of serum was incubated
with 100 μL of TRAP 5b reaction buffer (2.5 mM naph-
thol AS-BI phosphate, 50 mM sodium tartrate and 0.12 M
sodium acetate, 2% NP-40, and 1% ethylene glycol mono-
methyl ether, pH 6.1) for 30 min at 37°C, and the reaction
was stopped by adding 120 μL of 0.1 M NaOH. Fluores-
cence was measured at an excitation wavelength of
405 nm and an emission wavelength of 520 nm.
Cell viability assay
BMMs (1 × 104 cells/well in a 96-well plate) were cul-
tured with or without WEAO (10–160 μg/mL) in the
presence of M-CSF (60 ng/mL) for 2 days, and the via-
bility of BMMs was evaluated with Cell Counting Kit-8
assay (Dojindo Molecular Technologies Inc., Rockville,
MD, USA) according to the manufacturer’s protocol.
Animals and RANKL-induced osteoporosis model
All animal experiments were carried out according to
the protocols (permission number: 12–090) approved by
the Institutional Animal Care and Use Committee
Guidelines of Korea Institute of Oriental Medicine.
5-week-old male ICR mice were purchased from Orient
Bio Inc. (Seoul, Korea) and housed under constant envir-
onmental conditions (22 ± 1°C, 55 ± 10% humidity,
and 12 h light/dark cycle) with free access to a standard
animal diet and water. 7-week-old mice were orally
administered with vehicle (distilled water) or WEAO
(0.25 g/kg of body weight) twice daily for consecutive5 days, and RANKL (1 mg/kg of body weight) or PBS was
intraperitoneally injected on days 3 and 4. On day 6, fast-
ing blood samples and the right femurs were collected.
Measurement of serum markers of bone resorption and
bone formation
Serum levels of C-terminal cross-linked telopeptide of
type I collagen (CTX) and osteocalcin were measured
using a RatLaps EIA kit (Immunodiagnostic Systems
Inc., Fountain Hills, AZ, USA) and a mouse osteocalcin
EIA kit (Biomedical Technologies Inc., Stoughton, MA,
USA), respectively.
Micro-computed tomography (micro-CT) analysis
Micro-CT scanning of the distal femur was carryout
out on SkyScan 1076 CT scanner system (SkyScan N.V.,
Kontich, Belgium). The scanned images were recon-
structed and analyzed using SkyScan CT Analyzer (Sky-
scan). The structural parameters including trabecular
bone volume per tissue volume, thickness, separation, and
number were measured in the distal femoral metaphysis
between 0.54 and 1.46 mm distal to the growth plate.
Bone resorption assay
Primary pre-osteoblasts were obtained from calvariae of
newborn ICR mice (Orient Bio Inc.) by a sequential en-
zymatic digestion method described previously [25]. To
obtain mature osteoclasts, bone marrow cells (1.5 × 107
cells) and pre-osteoblasts (1.5 × 106 cells) were cocul-
tured in the presence of 1α,25-dihydroxyvitamin D3 (10
nM) and prostaglandin E2 (100 nM) in a 10-cm dish
coated with collagen gel (Cellmatrix type I-A, Nitta Gel-
atin Inc., Osaka, Japan) for 6 days. The plates were
treated with collagenase (Sigma-Aldrich), and mature
osteoclasts were placed on an Osteo Assay Surface plate
(Corning Inc., Corning, NY, USA), allowed to settle for
2 h, and then cultured with or without WEAO. After
24 h of culture, cells were stained for TRAP activity. Re-
sorption pits by osteoclasts were photographed and ana-
lyzed by using ImageJ software, after removing cells with
sodium hypochlorite.
Quantitative real-time polymerase chain reaction (qPCR)
analysis
Total RNA was extracted with RNA-spin total RNA Ex-
traction Kit (Bioneer, Daejeon, Korea), and fist-strand
cDNA was synthesized from 1 μg of total RNA with Accu-
Power RT-PreMix (Bioneer). SYBR green-based qPCR was
performed on the Applied Biosystems 7500 Real-Time
PCR System (Foster City, CA, USA) with cDNA diluted to
1:5, 10 pmol of primers, and AccuPower GreenStar qPCR
Master Mix (Bioneer). The following mouse-specific pri-
mer sets were used: c-Fos, 5′-CGGGTTTCAACGCCGA
CTAC-3′ (forward) and 5′-AAAGTTGGCACTAGAGAC
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GAAAATAACA-3′ (forward) and 5′-TGTGGGATGTG
AACTCGGAA-3′ (reverse); Id2, 5′-CGGTGAGGTCCGT
TAGGAAAA-3′ (forward) and 5′-CATGTTGTAGAGC
AGACTCATCG-3′ (reverse); MafB, 5′-AGTGTGGAGG
ACCGCTTCTCTG-3′ (forward) and 5′-CTGGACGCG
TTTATACCTGC-3′ (reverse); hypoxanthine phosphoribo-
syltransferase, 5′-CCTAAGATGAGCGCAAGTTGAA-3′
(forward) and 5′-CCACAGGACTAGAACACCTGCTAA-3′
(reverse). All reactions were run in triplicate, and data
were analyzed using the 2-ΔΔCT method. Hypoxanthine
phosphoribosyltransferase was used as an internal control.
Western blot analysis
Cells were washed with ice-cold PBS and lysed with RIPA
buffer (Millipore, Temecula, CA, USA) supplemented with
protease-inhibitor and phosphatase-inhibitor cocktail tab-
lets (Roche Applied Science, Indianapolis, IL, USA) on ice
for 30 min. The cell extracts were centrifuged at 10,000 g,
4°C for 10 min. Equal amounts of proteins (30 μg) were
boiled in sodium dodecyl sulfate (SDS) sample buffer for
5 min and separated by 10% SDS-polyacrylamide gel elec-
trophoresis and transferred to a polyvinylidene fluoride
membrane (GE Healthcare, Buckinghamshire, UK). After
blocking with 5% nonfat dry milk, the membranes were
probed with the indicated primary antibodies, followed by
secondary antibodies conjugated with horseradish perox-
idase. Immunoreactive bands were visualized with Super-
Signal West Femto Maximum Sensitivity Substrate
(Thermo Fisher Scientific Inc., Rockford, IL, USA) using
Luminescent Image Analyzer LAS-4000 (Fuji Photo Film
Co., Tokyo, Japan).
Retroviral gene transduction
Retrovirus packaging and BMM infection by using retro-
viral vectors pMX-IRES-green fluorescent protein (GFP)
and pMX-constitutively active (CA)-NFATc1-IRES-GFP
were performed as described previously [24]. In brief,
retrovirus packaging was performed by transient trans-
fection of these pMX vectors into Plat-E retroviral pack-
aging cells (Cell Biolabs, San Diego, CA, USA). BMMs
were incubated with the viral supernatant from Plat-E
cells together with polybrene (6 μg/mL, Sigma-Aldrich)
and M-CSF (60 ng/mL) for 12 h. After removing viral
supernatant, BMMs were cultured in the presence of M-
CSF for 1 day and then treated as indicated.
Statistical analysis
Values are presented as mean ± SD in in vitro study and
mean ± SEM in in vivo study. Two-group comparisons
were performed with Student's t tests, while multiple-
group comparisons were performed with analysis of vari-
ance followed by Dunnett’s test. A p-value less than 0.05
was considered statistically significant.Results and discussion
WEAO inhibits RANKL-induced osteoclast differentiation
To determine whether WEAO affects osteoclast differenti-
ation, we examined the effect of WEAO on RANKL-
induced osteoclast differentiation from its precursor cells,
BMMs. Treatment of BMMs with M-CSF and RANKL for
4 days induced TRAP-positive multinucleated osteoclasts.
When WEAO was added to the BMM cultures simultan-
eously with RANKL, osteoclast differentiation was inhib-
ited by WEAO in a dose-dependent manner (Figure 1A
and B). WEAO did not affect the viability of BMMs at
concentrations less than 160 μg/mL (Figure 1C), indi-
cating that the inhibitory effect of WEAO on osteoclast
differentiation did not result from cytotoxicity. WEAO
at 80 μg/mL almost completely inhibited osteoclast
differentiation, without affecting cell viability. Thus,
80 μg/mL of WEAO was used for the subsequent exper-
iments to elucidate the mechanisms underlying its anti-
osteoclastogenic effect. To determine at which stage
WEAO inhibits osteoclast differentiation, WEAO was
added to the BMM cultures on days 0–3. WEAO effect-
ively inhibited RANKL-induced osteoclast differentiation
when added simultaneously with RANKL (day 0). In con-
trast, WEAO did not affect RANKL-induced osteoclast
differentiation when added on days 2 and 3 (Figure 1D).
These results suggest that WEAO inhibits early cellular
events for RANKL-induced osteoclastogenesis.
Previous phytochemical studies have shown that flavo-
noids (e.g., tectochrysin and chrysin), diarylheptanoids
(e.g., yakuchinone A and yakuchinone B), and sesquiter-
penes (e.g., nootkatone) are abundant in ethanol extracts
of the fruits of A. oxyphylla [17,26]. In accordance with
this, we identified chrysin, tectochrysin, and nootkatone
in 75% ethanol extract of the fruits of A. oxyphylla
HPLC analysis, based on their HPLC retention times and
UV absorption spectra (data not shown). Among these
compounds, nootkatone was relatively abundant in
WEAO (Figure 1E). Nootkatone has been shown to have
multiple pharmacological properties including anti-
inflammatory [27], anti-allergic [28], antiplatelet [29], and
anti-obesity [30] activities. We found that nootkatone
(10–40 μM) dose-dependently inhibits RANKL-induced
osteoclast differentiation without affecting cell viability
(Figure 1F and G). Although further study is needed to
isolate and characterize the chemical constituents of
WEAO, our results suggest that nootkatone might be one
of the active constituents contributing to the inhibitory ef-
fect of WEAO on osteoclast differentiation.
WEAO inhibits RANKL-induced NFATc1 expression in
osteoclast precursors
We next investigated the effect of WEAO on the expres-
sion of transcription factors regulating osteoclast differ-
entiation. RANKL stimulated the mRNA and protein
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Figure 1 Effect of WEAO on RANKL-induced osteoclast differentiation in BMMs. (A, B) BMMs were cultured with vehicle (distilled water) or
WEAO (10–160 μg/mL) in the presence of M-CSF (60 ng/mL) and RANKL (100 ng/mL) for 4 days. (A) Cells were fixed and stained for TRAP activity.
Scale bar, 200 μm. (B) The number of osteoclasts (Oc) was counted. (C) The viability of BMMs was determined by Cell Counting Kit-8 assay.
(D) BMMs were cultured in the presence of M-CSF and RANKL for 4 days, and WEAO (80 μg/mL) was added to the BMM cultures at the indicated
days. The number of osteoclasts was counted on day 4. (E) HPLC chromatograms of WEAO and a standard mixture of chrysin, tectochrysin, and
nootkatone at 203 nm. (F) BMMs were cultured with vehicle (dimethylsulfoxide) or nootkatone (10–40 μM) in the presence of M-CSF and RANKL
for 4 days, and the number of osteoclasts was counted. (G) The effect of nootkatone on viability of BMMs. *p < 0.05; **p < 0.01 versus
vehicle-treated control.
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RANKL-induced NFATc1 expression (Figure 2A and B).
To investigate whether the reduction of NFATc1 is re-
sponsible for the anti-osteoclastogenic action of WEAO,
BMMs were transduced with retroviruses harboring con-
trol GFP or CA-NFATc1-GFP vectors. WEAO blocked
RANKL-induced osteoclast differentiation in BMMs in-
fected with control GFP, whereas the ectopic expression of
CA-NFATc1 rescued the inhibitory effect of WEAO
(Figure 2C). These results suggest the involvement of
NFATc1 in the anti-osteoclastogenic effect of WEAO and
further confirmed that the anti-osteoclastogenic effect of
WEAO is not due to cytotoxicity.
The transcription factor c-Fos is also essential for os-
teoclastogenesis and functions as a key upstream activa-
tor of NFATc1 during osteoclastogenesis [31]. Similar to
its effect on NFATc1 expression, WEAO abrogated
RANKL-induced c-Fos mRNA and protein expression
(Figure 2A and B). In addition to up-regulation oftranscriptional activators, RANKL stimulates NFATc1
expression and osteoclastogenesis by suppression of sev-
eral transcriptional repressors including Ids and MafB
[13]. The expression of Id helix-loop-helix transcription
factors is suppressed by RANKL during osteoclastogen-
esis, and Ids negatively regulate RANKL-induced osteo-
clastogenesis by down-regulating the expression of
osteoclast-associated receptor and NFATc1 through
attenuation of DNA binding ability of Mitf [32]. MafB
expression is also down-regulated by RANKL, and
MafB suppresses osteoclastogenesis by interfering with
transcriptional activities of c-Fos, Mitf, and NFATc1
[33]. Consistent with the previous reports, RANKL
markedly reduced the expression of Id2 and MafB
in BMMs. WEAO increased Id2 expression and inhib-
ited RANKL-induced down-regulation of Id2 and
MafB expression (Figure 2A). It has been shown that
Id2 and MafB do not affect RANKL-induced c-Fos ex-
pression [33,34]. Thus, these results collectively suggest
ARANKL (day) 0 1 2 3 0 1 2 3
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Figure 2 Effect of WEAO on the gene expression of transcription factors involved in osteoclast differentiation. (A, B) BMMs were
cultured with vehicle (distilled water) or WEAO (80 μg/mL) in the presence of M-CSF (60 ng/mL). Total RNA and cell lysates were obtained
following stimulation with RANKL (100 ng/mL) for the indicated times. (A) Relative mRNA expression levels of NFATc1, c-Fos, Id2, and MafB were
determined by qPCR. **p < 0.01 versus vehicle-treated control. (B) Total cell lysates were subjected to Western blot analysis with antibodies
against NFATc1, c-Fos, and p38. p38 was used as a loading control. (C) BMMs transduced with retroviruses expressing either pMX-IRES-GFP (pMX)
or pMX-CA-NFATc1-IRES-GFP (pMX-CA-NFATc1) were cultured with vehicle or WEAO (80 μg/mL) in the presence of M-CSF (60 ng/mL) and RANKL
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Figure 3 Effect of WEAO on RANKL-induced activation of
MAPKs and NF-κB in BMMs. BMMs were pretreated with vehicle
or WEAO (80 μg/mL) for 3 h and then stimulated with RANKL
(100 ng/mL) for the indicated times. Total cell lysates were subjected
to Western blot analysis using the indicated antibodies.
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sion by suppressing the induction of its up-stream acti-
vator c-Fos as well as the down-regulation of its
negative regulators, Id2 and MafB, thereby inhibiting
osteoclastogenesis.
WEAO alters RANKL-induced activation of MAPKs and NF-κB
Binding of RANKL to RANK leads to the activation of
MAPK and NF-κB pathways, which are implicated in
osteoclast differentiation by involving c-Fos and NFATc1
induction [7-9,35,36]. To get more insights into the
mechanisms underlying the anti-osteoclastogenic effect
of WEAO, we investigated whether WEAO affects the
early signaling events trigged by RANKL. Treatment of
BMMs with RANKL increased the phosphorylation
of JNK and p38 MAPKs within 5 min, reached the
maximum at 15 min, and then decreased thereafter
(Figure 3). Pretreatment of BMMs with WEAO in-
creased the phosphorylation of JNK and p38 and pro-
longed RANKL-induced phosphorylation of JNK and
p38. RANKL stimulated the classical NF-κB signaling
pathway, determined by IκBα phosphorylation and subse-
quent degradation. Pretreatment of BMMs with WEAO
increased IκBα phosphorylation but markedly suppressed
RANKL-induced IκBα phosphorylation and degradation
(Figure 3). Thus, these results suggest that WEAO inhibits
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pressing the classical NF-κB signaling pathway.
It has been reported that RANKL down-regulates
MafB expression through JNK and p38 MAPK pathways
but not the classical NF-κB pathway [33]. Thus, our re-
sults suggest that WEAO inhibits RANKL-mediated
MafB down-regulation independently of these MAPK
pathways. However, the mechanisms underlying the in-
hibitory effects of WEAO on RANKL-mediated down-
regulation of MafB and Id2 remain to be elucidated.WEAO does not affect bone resorbing activity of mature
osteoclasts
When attached to bone matrix, osteoclasts polarize their
membrane to bone surface and secret hydrochloric acid and
acidic proteases which degrade bone matrix in a sealed
compartment [2]. To investigate whether WEAO affects re-
sorbing activity of mature osteoclasts, mature osteoclasts
were generated from the coculture of bone marrow cells
and pre-osteoblasts and seeded on a plate coated with an in-
organic crystalline calcium phosphate designed to mimic
bone mineral. After 24 h of culture, numerous pits resorbed
by osteoclasts were formed on the plate. WEAO did
not affect osteoclast number and the resorbed area at
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Figure 4 Effect of WEAO on bone resorbing activity of mature osteoc
inorganic crystalline calcium phosphate and then cultured with vehicle or
and resorption pits formed by osteoclasts were photographed. Scale bar, 2
significant. (C) The total area of resorption pits was measured.does not directly affect bone resorbing activity of ma-
ture osteoclasts.
WEAO inhibits RANKL-induced bone loss in vivo
Increased RANKL activity is involved in bone destruc-
tion in various bone diseases [2]. Having found that
WEAO inhibits RANKL-induced osteoclast differenti-
ation in vitro, we next examined the in vivo effect of
WEAO on osteoclast-mediated bone destruction using a
murine model of bone loss by RANKL injection. Intra-
peritoneal injections of RANKL into mice rapidly induce
bone loss by stimulating osteoclast differentiation and
function [37]. RANKL injections caused a severe trabecu-
lar bone loss at the distal femoral metaphysis (Figure 5A).
Quantitative micro-CT analysis of trabecular bone micro-
architecture showed that RANKL injections led to a
marked decrease in trabecular bone volume per tissue vol-
ume, trabecular thickness, and trabecular number, with an
increase in trabecular separation. Oral administration of
WEAO (0.25 g/kg twice daily) significantly attenuated
RANKL-induced changes in trabecular bone microarchi-
tecture, except trabecular thickness (Figure 5A and B). We
next investigated the changes in serum TRAP 5b activity,
CTX levels, and osteocalcin levels, which are used for
markers of osteoclast numbers, bone resorption, and bone
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Figure 5 Effect of WEAO on RANKL-induced bone destruction in mice. Mice were orally administrated with vehicle (n = 8 per group) or
WEAO (0.25 g/kg, n = 7) twice daily for 5 days, and RANKL (1 mg/kg) was injected intraperitoneally on days 3 and 4. Blood serum and right
femur were collected on day 6. (A) Representative micro-CT images of the distal femurs from each group. (B) Quantitative micro-CT analysis of
trabecular bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp) in the
distal femoral metaphysis. (C) Serum TRAP 5b activity. (D) Serum CTX levels. (E) Serum osteocalcin levels. *p < 0.05; **p < 0.01; ***p < 0.001; n.s,
not significant.
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induced by RANKL injections (Figure 5C and D). There
were no significant differences in serum osteocalcin levels
among the groups (Figure 5E). Therefore, it is likely that
the protective effect of WEAO against bone destruction is
mainly due to suppression of bone resorption through in-
hibition of osteoclast differentiation. Our results clearly
showed that WEAO at a dose of 0.25 g/kg twice daily at-
tenuates RANKL-induced osteoclast differentiation and
bone destruction in vivo. However, such beneficial effects
of WEAO were not observed at a dose of 0.75 g/kg (data
not shown). Therefore, further studies are needed to more
thoroughly characterize the dose response effects of
WEAO on bone metabolism. In addition, the beneficial ef-
fect of WEAO in bone disease states such as postmeno-
pausal osteoporosis and lytic bone metastasis remains to
be investigated.
Conclusions
This study demonstrated that WEAO inhibits osteoclast
differentiation by suppressing RANKL-induced NFATc1
expression in osteoclast precursors. The reduction ofNFATc1 expression by WEAO was attributable to sup-
pression of RANKL-induced up-regulation of its positive
regulators, NF-κB and c-Fos, and down-regulation of its
negative regulators, Id2 and MafB. Consistent with the
in vitro results, oral administration of WEAO attenuated
RANKL-induced bone destruction by inhibiting osteo-
clast differentiation. Given the role of excessive RANKL
activity in pathological bone loss, our findings suggest
that WEAO may be useful for the prevention and treat-
ment of bone metabolic diseases associated with exces-
sive osteoclastic bone resorption.
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